The Hyperoxaluria drugs in development market research report provides comprehensive information on the therapeutics under development for Hyperoxaluria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hyperoxaluria. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Hyperoxaluria - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hyperoxaluria and features dormant and discontinued products.

GlobalData tracks 17 drugs in development for Hyperoxaluria by 16 companies/universities/institutes. The top development phase for Hyperoxaluria is discovery with six drugs in that stage. The Hyperoxaluria pipeline has 17 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Hyperoxaluria pipeline products market are: Intellia Therapeutics, Vivet Therapeutics and Arbor Biotechnologies.

The key targets in the Hyperoxaluria pipeline products market include Hydroxyacid Oxidase 1 (Glycolate Oxidase or HAO1 or EC, L-Lactate Dehydrogenase A Chain (Cell Proliferation Inducing Gene 19 Protein or LDH Muscle Subunit or Renal Carcinoma Antigen NY REN 59 or LDHA or EC, and Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3).

The key mechanisms of action in the Hyperoxaluria pipeline product include Hydroxyacid Oxidase 1 (Glycolate Oxidase or HAO1 or EC Inhibitor with three drugs in Phase II. The Hyperoxaluria pipeline products include two routes of administration with the top ROA being Oral and six key molecule types in the Hyperoxaluria pipeline products market including Gene Therapy, and Small Molecule.

Hyperoxaluria overview

Hyperoxaluria, a rare condition, manifests with recurrent kidney and bladder stones, often progressing to life-threatening end-stage renal disease (ESRD). The condition arises from the overproduction of oxalate, leading to abnormally high levels in urine. Primary hyperoxaluria types 1, 2, and 3 are caused by mutations in the AGXT, GRHPR, and HOGA1 genes, respectively. These genes guide the production of enzymes crucial for breaking down amino acids and other compounds. The enzyme from the HOGA1 gene plays a role in amino acid breakdown, resulting in the formation of glyoxylate, further processed by enzymes from the AGXT and GRHPR genes.

For a complete picture of Hyperoxaluria’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.